Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Mevrometostat

Small molecule · Inhibitor of Enhancer of zeste homolog 2 (EZH2) · developed by Pfizer

Phase 3 Most advanced trial
PFE Developer
1 Registered trials

What is Mevrometostat?

Mevrometostat (PF-06821497) is an orally available small molecule that selectively binds to and inhibits EZH2, the catalytic subunit of polycomb repressive complex 2. By preventing methylation of histone H3 on lysine 27, it alters gene expression patterns and reduces proliferation of EZH2-expressing cancer cells. It is being studied in metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PF-06821497
Drug type
Small molecule
Targets
Enhancer of zeste homolog 2 (EZH2)
Mechanism
Inhibitor of Enhancer of zeste homolog 2 (EZH2)
Pathways
Histone H3 lysine 27 methylation, PRC2-mediated gene silencing, Cancer cell proliferation
Therapy area
Oncology
Developer
Pfizer (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
S4L4MM20B6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06629779 Phase 3 Metastatic Castration-Resistant Prostate Cancer Active not recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration-Resistant Prostate Cancer

Other drugs acting on EZH2

More from Pfizer

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Mevrometostat

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.